Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693
NCT00493818
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
70
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Interventions
DRUG:
GSK690693
Sponsor
GlaxoSmithKline